Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (DE:26CA)
FRANKFURT:26CA
26CA Stock Chart & Stats
€1.82
-€0.11(-4.34%)
At close: 4:00 PM EST
€1.82
-€0.11(-4.34%)
Day’s Range― - ―
52-Week Range€1.63 - €5.17
Previous CloseN/A
Volume0.00
Average Volume (3M)1.07K
Market Cap
$1.81B
Enterprise Value€2.93B
Total Cash (Recent Filing)$153.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Mar 03, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding984,965,150
10 Day Avg. Volume2,004
30 Day Avg. Volume1,072
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-3.66
Price to Sales (P/S)121.07
P/FCF Ratio-4.48
Enterprise Value/Market Cap1.62
Enterprise Value/Revenue35.53
Enterprise Value/Gross Profit37.49
Enterprise Value/Ebitda-12.61
Forecast
1Y Price Target
$6.07Price Target Upside233.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial TractionANKTIVA's strong early commercial traction in BCG-unresponsive CIS NMIBC with unit sales up 467% highlights its expanding adoption.
Regulatory ApprovalFDA approval in NMIBC and emerging utility across solid and liquid tumors positions ANKTIVA as a versatile immunorestorative cytokine backbone.
Sales GrowthANKTIVA's sales reached $26.4M, reflecting 60% quarter-over-quarter growth, driven by increasing adoption in U.S. urology practices.
Bears Say
Regulatory ConcernsThe FDA raised concerns about the single-arm design of the QUILT-3.032 Cohort B study during the Type A meeting regarding ANKTIVA’s supplemental BLA.
ImmunityBio News
26CA FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.63 and its highest was €5.17 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $1.81B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Mar 03, 2026 which is in 114 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Nov 04, 2025. The company reported -€0.061 earnings per share for the quarter, beating the consensus estimate of -€0.092 by €0.032.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.1.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 984,965,150 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.061 in its last earnings report, beating expectations of -€0.092. Following the earnings report the stock price went down -8.163%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in DE:26CA
ImmunityBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.07 (233.67% Upside)
$6.07 (233.67% Upside)
Blogger Sentiment
Bullish
DE:26CA Sentiment 75%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.36%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
26CA Stock 12 Month Forecast
Average Price Target
€6.07
▲(233.67% Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Options Prices
Currently, No data available
---